NVS
Novartis AG ADR (NYSE: NVS) reported stronger-than-expected sales growth in Q2 2026 on the back of a range...
Article Summary
HOLD- Novartis AG ADR (NYSE: NVS) reported stronger-than-expected sales growth in Q2 2026 on the back of a range of new products, including Rhapsido, which was approved in the U.S. and EU in September and Rhapsidio, a chronic-rash treatment approved in Europe in April, generating $64 million in sales already.
- Novartis AG ADR reported higher sales of $14.4 billion, slightly above expectations, though net profit fell 19% to $3.2 billion due to higher interest and tax expenses.
- The Basel-based company confirmed its targets for 2026 and said it is still aiming for low single-digit sales growth for the whole year despite facing patent expirations for Entresto, a flagship heart-failure drug, which generated $7.7 billion in sales in 2025.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 5.6% | 25% | 35.0 ptsBelow Screener (5.6%) - Weak growth |
| EPS Growth Next 5Y ? | 6.1% | 25% | 20.0 ptsWeak (6.1%) - Low expectations |
| Target Price Upside ? | 1.8% | 20% | 10.0 ptsNear/At Target (1.8%) - Target: $153.24 vs Current: $156.06 |
| Gross Margin % ? | 74.6% | 15% | 100.0 ptsExceptional (74.6%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -8.5% | 15% | 20.0 ptsBarely a Dip (-8.5%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About NVS
- Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
- The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD).
- It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta.
- The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology.
- It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol.
- Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.